Voyager Therapeutics, Inc.
NASDAQ:VYGRBiotechnology
+$0.09 today
- Market cap
- $103.92M
- Beta
- 1.25
- P/E (TTM)
- -1.9
- EPS (TTM)
- -$1.96
Volume 0.84M
Average 0.54M
VYGR Total Non-current Liabilities
All obligations due after more than one year.
Voyager Therapeutics, Inc.NASDAQ: VYGR
Total Non-current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total non-current liabilities falls 30.1% from a year ago
Total non-current liabilities stood at $28.2M at the end of Q1 FY2026, down 30.1% from a year earlier and down 4.9% from the prior quarter. Over 3 fiscal years it compounded at +2.2% a year.
Context
- Total non-current liabilities amounted to 12.9% of total assets at the end of Q1 FY2026, up 1.4 pp from a year earlier.
- Total non-current liabilities increased in 1 of the last 3 fiscal years.
What to watch
Whether total non-current liabilities keeps falling in the next quarterly balance sheet after a -30.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Non-current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 29.66M USD
- Year-over-year change
- -31.8%
- 4-year CAGR
- -11.3%
| Period | Period end | Total Non-current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 29.66M | -31.8% |
| FY2024 | 2024-12-31 | 43.5M | -13.8% |
| FY2023 | 2023-12-31 | 50.45M | +81.8% |
| FY2022 | 2022-12-31 | 27.75M | -42.0% |
| FY2021 | 2021-12-31 | 47.82M | — |
Total Non-current Liabilities vs competitors
How VYGR compares with its peers on the latest reported figures
- VYGR's Mar 2026 total non-current liabilities of $28.2M is the 5th highest of the 11 companies compared; the peer median is $18.43M.
- Its year-over-year change of -30.1% is the 8th highest of 10, against a peer median of -10.5%.
- Total non-current liabilities amounts to 12.9% of total assets for VYGR, versus a peer median of 18.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $151.67M | -17.3% | +78.5% | 48.2% | |
| Mar 2026 | $88.75M | -4.1% | -3.5% | 22.4% | |
| Mar 2026 | $82.75M | -22.3% | +11.9% | 74.8% | |
| Mar 2026 | $45.47M | -10.5% | +38.7% | 13.6% | |
| Mar 2026 | $28.2M | -30.1% | +2.2% | 12.9% | |
| Mar 2026 | $19.68M | -59.5% | -26.8% | 8.0% | |
| Mar 2026 | $17.18M | +3.5% | +2.1% | 4.0% | |
| Mar 2026 | $16.5M | -10.0% | -3.5% | 25.7% | |
| Mar 2026 | $10.59M | +6.5% | +445.3% | 32.0% | |
| Mar 2026 | $0 | -100.0% | — | 0.0% | |
SGMTSagimet Biosciences Inc. | Mar 2026 | $0 | — | — | 0.0% |
| Peer median (excluding VYGR) | $18.43M | -10.5% | +7.0% | 18.0% | |
Competitors are the stored peer set for VYGR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 117.43M | 98.96M | 68.8M | 71.37M | 65.3M |
| Short-term Investments | 15.11M | 19.89M | 162.07M | 195.32M | 131.15M |
| Net Receivables | 748K | 639K | 84.46M | 4.49M | 1.76M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 1.7M | 4.23M | 2.63M | 2.87M | 4.48M |
| Total Current Assets | 136.7M | 124.5M | 319.68M | 276.81M | 202.69M |
| Property, Plant & Equipment (Net) | 55.38M | 33.34M | 30M | 47.66M | 41.61M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 65.7M | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 1.78M | 1.52M | 1.59M | 2.87M | 7.98M |
| Total Non-current Assets | 57.16M | 34.86M | 31.6M | 116.24M | 49.59M |
| Total Assets | 193.86M | 159.36M | 351.28M | 393.05M | 252.28M |
| Account Payables | 574K | 2.57M | 1.6M | 4M | 5.01M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 33.89M | 59.38M | 42.88M | 24.39M | 1.59M |
| Other Current Liabilities | 5.02M | 4.56M | 6.61M | 6.75M | 9.09M |
| Total Current Liabilities | 50.98M | 72.59M | 64.51M | 49.79M | 26.54M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 8.21M | 6.45M | 32.36M | 6M | 0 |
| Other Non-current Liabilities | 1M | 1M | 1M | 1M | 1M |
| Total Non-current Liabilities | 47.82M | 27.75M | 50.45M | 43.5M | 29.66M |
| Total Liabilities | 98.8M | 100.34M | 114.96M | 93.29M | 56.2M |
| Common Stock | 38K | 38K | 44K | 55K | 59K |
| Retained Earnings | (347.1M) | (393.51M) | (261.18M) | (326.18M) | (445.91M) |
| Accumulated OCI | (138K) | (219K) | (48K) | (407K) | 32K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 95.06M | 59.02M | 236.32M | 299.76M | 196.08M |
| Total Debt | 44.18M | 23.13M | 20.29M | 43.73M | 36.5M |
| Net Debt | (73.25M) | (75.83M) | (48.51M) | (27.64M) | (28.8M) |
Voyager Therapeutics, Inc.
NASDAQ:VYGR
Intrinsic Alpha fair value
Locked
Current Price
$1.67
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.